Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures

[1]  J. Bongaarts,et al.  United Nations Department of Economic and Social Affairs, Population Division World Family Planning 2020: Highlights, United Nations Publications, 2020. 46 p. , 2020 .

[2]  T. Peters,et al.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial , 2019, Osteoporosis International.

[3]  C. Cooper,et al.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.

[4]  V. Gudnason,et al.  Dietary intake is associated with risk of multiple myeloma and its precursor disease , 2018, PloS one.

[5]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[6]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[7]  V. Gudnason,et al.  Imminent risk of fracture after fracture , 2017, Osteoporosis International.

[8]  D. Dempster,et al.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[10]  S. Norgren,et al.  Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics. , 2016, The Journal of clinical endocrinology and metabolism.

[11]  P. Vestergaard,et al.  Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective , 2015, Osteoporosis International.

[12]  S. Silverman,et al.  The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group , 2014, Osteoporosis International.

[13]  C. Cooper,et al.  Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.

[14]  J. Kanis,et al.  The distribution of FRAX®-based probabilities in women from Japan , 2012, Journal of Bone and Mineral Metabolism.

[15]  V. Gudnason,et al.  Serum levels of marine-derived n-3 fatty acids in Icelanders, Japanese, Koreans, and Americans--a descriptive epidemiologic study. , 2012, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[17]  J. Compston,et al.  A comparison of case-finding strategies in the UK for the management of hip fractures , 2012, Osteoporosis International.

[18]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[19]  W. Leslie,et al.  Time since prior fracture is a risk modifier for 10‐year osteoporotic fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Kim Brixen,et al.  Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population‐Based Cohort Study of 169,145 Cases During 1977–2001 , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  O. Johnell,et al.  BMD, clinical risk factors and their combination for hip fracture prevention , 2009, Osteoporosis International.

[22]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[23]  G. Dinant,et al.  Clinical subsequent fractures cluster in time after first fractures , 2008, Annals of the rheumatic diseases.

[24]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[25]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[26]  V. Gudnason,et al.  Inaccuracy in self-report of fractures may underestimate association with health outcomes when compared with medical record based fracture registry , 2007, European Journal of Epidemiology.

[27]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[28]  J. Lauritsen,et al.  Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study , 2006, Osteoporosis International.

[29]  O. Johnell,et al.  Evidence From Data Searches and Life‐Table Analyses for Gender‐Related Differences in Absolute Risk of Hip Fracture After Colles' or Spine Fracture: Colles' Fracture as an Early and Sensitive Marker of Skeletal Fragility in White Men , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[31]  O. Johnell,et al.  Fracture risk following an osteoporotic fracture , 2004, Osteoporosis International.

[32]  O. Johnell,et al.  Excess mortality after hospitalisation for vertebral fracture , 2004, Osteoporosis International.

[33]  O. Johnell,et al.  The components of excess mortality after hip fracture. , 2003, Bone.

[34]  O. Johnell,et al.  International Variations in Hip Fracture Probabilities: Implications for Risk Assessment , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[36]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[37]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  K. E. Dretakis,et al.  Possible Predisposing Factors for the Second Hip Fracture , 1998, Calcified Tissue International.

[39]  T. Peters,et al.  SYSTEMATIC SCREENING USING FRAX LEADS TO INCREASED USE OF, AND ADHERENCE TO, ANTI-OSTEOPOROSIS MEDICATIONS: THE UK SCOOP TRIAL , 2018 .

[40]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[41]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[42]  J. Kanis,et al.  The potential impact of new National Osteoporosis Foundation guidance on treatment patterns , 2009, Osteoporosis International.

[43]  Pharmacokinetic Subgroup.  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT PAPER ON THE DEVELOPMENT OF A GUIDELINE ON THE USE OF PHARMACOGENOMIC METHODOLOGIES IN THE PHARMACOKINETIC EVALUATION OF MEDICINAL PRODUCTS , 2009 .

[44]  O. Johnell,et al.  Mortality after osteoporotic fractures , 2004, Osteoporosis International.

[45]  O. Johnell,et al.  Colles' fracture as an early and sensitive marker of skeletal fragility in men , 2003 .

[46]  O. Johnell,et al.  Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture , 2001, Osteoporosis International.

[47]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[48]  O. Johnell,et al.  Long-Term Risk of Osteoporotic Fracture in Malmö , 2000, Osteoporosis International.